Pharmacyclics — Technical Presentation (December 2012)
16 slides from Pharmacyclics's technical presentation, Dec 10, 2012
Slide 1: Disclosures
Disclosures ANDREW M. EVENS, DO, MSc RESEARCH FUNDING: EMPLOYEE: STOCKHOLDER: CONSULTANT: SCIENTIFIC ADVISORY BOARD:
Slide 2: A Phase II Multicenter Study of the Histone Deacetylase Inhibitor Abexinostat in FL and MCL
A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI- 24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) ‘Division of Hematology/Oncology, The University of Massachusetts Medical School, Worcester, MA; ?Nebraska Medical Center,
Slide 3: HDAC Inhibitors
HDAC Inhibitors NH-C- CH, ci at , (CHL), HDAC HAL y Ke “Ac Ac “condensed” \ “open” + HDAC inhibitor Inhibition of HDAC (histone deacetylase) activity — Induces acetylation of histones and other cellular proteins — Results in the re-expression of silenced genes (e.g., p21) = Leads to tumor cell apopt
Slide 4: Abexinostat (PCI-24781) — an Oral HDAC Inhibitor
Abexinostat (PCI-24781) — an Oral HDAC Inhibitor = om Orally bioavailable with broad spectrum HDAC inhibition Strong binding affinity (< 20nM Ki) to all Class | and IIb isoforms except for HDAC8 (Ki = 200nM) Potent anti-tumor activities in lymphoma cell lines Tested in > 250 patients with solid tumo
Slide 5: PCYC-0403: Phase I/II Study in Relapsed/Refractory Lymphoma Patients
PCYC-0403: Phase I/II Study in Relapsed/Refractory Lymphoma Patien * Phase |: Dose escalation (reported at ASH 2009, Evens et al) — N= 25 (in 4 dose cohorts) — Clinical activity noted in follicular lymphoma (FL) and mantle cell lymphoma (MCL) patients: + In FL (n=4): 1 CR, 1 PRand 2 SD + In MCL (n=2
Slide 6: Subject Eligibility in Phase II of PCYC-0403
Subject Eligibility in Phase Il of PCYC-0403 * Pathologically confirmed FL or MCL * Received one to four prior regimens (prior allogeneic bone marrow transplant is excluded) * Adequate organ function * ECOG Performance Status < 1 * No CNS lymphoma * No use of corticosteroids > 20 mg prednisone equiv
Slide 7: Patient Characteristics in Phase II of PCYC-0403
Patient Characteristics in Phase II of PCYC- Gender: Female # (%) 8 (50.0) 2(14.3) 10 (33.3) Male # (%) 8 (50.0) 12 (85.7) 20 (66.7) Prior regimens, # (%) Median 2 3 3 Range 1-4 1-5 1-5 Rituximab/Zevalin 15 (93.8) 14 (100) 29 (96.7) CHOP/Chemo Combo* 14 (87.5) 13 (92.9) 27 (90.0) auto-SCT 5 (31.3) 5
Slide 8: Patient Disposition in Phase II of PCYC-0403
Patient Disposition in Phase Il of PCYC-0403 FL MCL Total (OG) (N=14 ) ( Time on Study (mos), # Median 94 24 5 Range 10-206 01-115 01-206 Patients Still on Study Treatment , # (%) 5(31.3) 2(14.3) 7(23.3) Patients Discontinued Treatment , # (%) 11(68.8) 12(85.7) _23(76.7) Primary Reasons for Disconti
Slide 9: Common AEs in Phase II of PCYC-0403
Common AEs In Phase II of PCYC-0403 (Events in = 20 % of Patients that were possibly related to Abexinostat) 0 © Grade 2 | Grade 4 Data cutoff as of May 31, 2012
Slide 10: Grade 3 or 4 AEs in Phase II of PCYC-0403
Grade 3 or 4 AEs in Phase II of PCYC-0403 (Events in > 5 % of Patients that were possibly related to Abexinostat) lAdverse Event Grade 3 # Grade 4 # ( Thrombocytopenia 2(6.7) 3 (10.0) Neutropenia 3 (10.0) 1(3.3) Fatigue 3 (10.0) 0(0) Anaemia 2(6.7) 0(0) Arthralgia 2 0(0) +One patient had a Grade 3 a
Slide 11: Best Response in Phase II of PCYC-0403
Best Response in Phase II of PCYC-0403* 64% 60% - 48% 4% 40% 36% 36% =PR SOR = SD 27% 28% =PD 24% 21% 20% 14% 0% if FL eta) NHLIMCL (Nett) ‘Total (Ne25) “inpatients who had baseline and posttreatment response assessments Data cutoff as of May 31, 2012 a
Slide 12: Maximum Change in Tumor Burden in Phase II of PCYC-0403
Maximum Change In Tumor Burden in Phase Il of PCYC-0403 ** * 12/14 (86%) evaluable FL patients had reductions in sum of product diameters (SPD), 5 of which had >75% reduction 100 go ~~ NHLMCL — Follicular 60 In TTT TT 182s" 6934 -60 % Change from Baseline SPD 240 2o7008 ‘The value is outside of the
Slide 13: Time on Study with Best Response in Phase II of PCYC-0403
Time on Study with Best Response in Phase IL of PCYC-0403 + 8/9 (89%) of FL responders were on study for > 8 months, 5 of which were still on study * Median duration of response was not reached for either FL or MCL group - —- NHL. > “100 Study cr 0 2 4 6 8 10 120 «140«16— 18 20 2 * SPO reduction > 7
Slide 14: A Case with CR in FL Patient
A Case with CR in FL Patient 56 yr-old male, diagnosed in Sept 2001, treated with RCHOP (Sept 2001 to Nov 2001), right neck base lumpectomy in 2001, and rituximab (Sept 2002 to Oct 2002) Started abexinostat on December 01 2010 PR noted at Cycle 4 and CR at Cycle 18, currently on treatment Pre-treatm
Slide 15: Conclusions
Conclusions * Abexinostat (PCI-24781) was active in relapsed/ refractory B-cell lymphoma with an ORR of 48% — In FL, 64% ORR was noted; responses were durable — In MCL, 27% ORR was noted * Safety profile consistent with this class of agents, but with less than 20% of patients experiencing Grade 23 c
Slide 16: Acknowledgements
Acknowledgements All the patients and their families who participated in the study. Colleagues from all the clinical centers. Colleagues from Pharmacyclics.
Pharmacyclics — Technical Presentation (December 2012) on 6ix